EE04378B1 - LAG-3 pleissimisteisendid - Google Patents

LAG-3 pleissimisteisendid

Info

Publication number
EE04378B1
EE04378B1 EEP199900581A EEP9900581A EE04378B1 EE 04378 B1 EE04378 B1 EE 04378B1 EE P199900581 A EEP199900581 A EE P199900581A EE P9900581 A EEP9900581 A EE P9900581A EE 04378 B1 EE04378 B1 EE 04378B1
Authority
EE
Estonia
Prior art keywords
lag
nucleotidic
seq
code
sequences
Prior art date
Application number
EEP199900581A
Other languages
English (en)
Estonian (et)
Inventor
Triebel Frdric
Mastrangeli Renato
Romagnani Sergio
Original Assignee
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Institut Gustave Roussy
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Sante Et De La Recherche Medicale (Inserm), Institut Gustave Roussy, Applied Research Systems Ars Holding N.V. filed Critical Institut National De La Sante Et De La Recherche Medicale (Inserm)
Publication of EE9900581A publication Critical patent/EE9900581A/xx
Publication of EE04378B1 publication Critical patent/EE04378B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EEP199900581A 1997-06-18 1998-06-03 LAG-3 pleissimisteisendid EE04378B1 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97401404A EP0900841A1 (fr) 1997-06-18 1997-06-18 Variantes d'épissure de LAG-3
PCT/EP1998/003307 WO1998058059A1 (fr) 1997-06-18 1998-06-03 Variants de lag-3 obtenus par epissage

Publications (2)

Publication Number Publication Date
EE9900581A EE9900581A (xx) 2000-08-15
EE04378B1 true EE04378B1 (xx) 2004-10-15

Family

ID=8229784

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900581A EE04378B1 (xx) 1997-06-18 1998-06-03 LAG-3 pleissimisteisendid

Country Status (17)

Country Link
EP (2) EP0900841A1 (fr)
JP (1) JP2002505582A (fr)
KR (1) KR100552526B1 (fr)
CN (1) CN1181201C (fr)
AT (1) ATE274057T1 (fr)
AU (1) AU740147B2 (fr)
BR (1) BR9810925A (fr)
CA (1) CA2293735A1 (fr)
DE (1) DE69825741T2 (fr)
DK (1) DK0977856T3 (fr)
EA (1) EA003086B1 (fr)
EE (1) EE04378B1 (fr)
ES (1) ES2227862T3 (fr)
IL (2) IL133544A0 (fr)
NO (1) NO996097L (fr)
PT (1) PT977856E (fr)
WO (1) WO1998058059A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100359A1 (en) * 2000-10-04 2003-05-29 Loose Timothy C. Audio network for gaming machines
EP1295895B1 (fr) * 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides et proteines se liant aux motifs glu-pro, compositions thérapeutiques les comprenant et leurs applications
SE0103423D0 (sv) * 2001-10-12 2001-10-12 Astrazeneca Ab Polymorphism
US20040258678A1 (en) * 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7867085B2 (en) 2003-01-16 2011-01-11 Wms Gaming Inc. Gaming machine environment having controlled audio and visual media presentation
US7367886B2 (en) 2003-01-16 2008-05-06 Wms Gaming Inc. Gaming system with surround sound
US7364508B2 (en) 2003-01-16 2008-04-29 Wms Gaming, Inc. Gaming machine environment having controlled audio and visual media presentation
US8313374B2 (en) 2003-02-14 2012-11-20 Wms Gaming Inc. Gaming machine having improved audio control architecture
US20060240024A1 (en) 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
FR2902101B1 (fr) * 2006-06-12 2012-12-28 Scras Peptides a activite anti-proliferative
WO2008063391A2 (fr) 2006-11-10 2008-05-29 Wms Gaming Inc. Jeux de pari à structure de jeu multiniveau
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US9412222B2 (en) 2013-09-20 2016-08-09 Igt Coordinated gaming machine attract via gaming machine cameras
AU2014323523B2 (en) 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
CA2935423C (fr) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Molecules d'anticorps anti-pd-1 et leurs utilisations
WO2015138920A1 (fr) 2014-03-14 2015-09-17 Novartis Ag Molécules d'anticorps anti-lag-3 et leurs utilisations
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
AU2016298227B9 (en) 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス,インコーポレーテッド Pd‐1及びctla‐4との免疫応答性を有する二重特異性並びにその使用方法
JP7000322B2 (ja) 2015-12-16 2022-02-04 メルク・シャープ・アンド・ドーム・コーポレーション 抗lag3抗体および抗原結合性フラグメント
CN110650974B (zh) 2017-02-10 2024-04-19 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
KR102721137B1 (ko) 2017-05-30 2024-10-25 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
CA3060984A1 (fr) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Traitement de tumeurs positives pour lag-3
AU2020276242B2 (en) 2019-05-13 2025-01-30 Regeneron Pharmaceuticals, Inc. Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
EP4680342A1 (fr) 2023-03-13 2026-01-21 Regeneron Pharmaceuticals, Inc. Combinaison d'inhibiteurs de pd-1 et d'inhibiteurs de lag-3 pour une efficacité améliorée dans le traitement d'un mélanome
WO2025106736A2 (fr) 2023-11-15 2025-05-22 Regeneron Pharmaceuticals, Inc. Combinaison d'inhibiteurs de pd-1 et d'inhibiteurs de lag-3 pour une efficacité améliorée dans le traitement du cancer du poumon
WO2026035866A1 (fr) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Traitement de patients atteints d'un cancer par des thérapies lymphocytaires infiltrant les tumeurs en combinaison avec un inhibiteur de lag-3 et un inhibiteur de pd-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134874B2 (ja) * 1986-08-21 2001-02-13 ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク T細胞表面タンパク質t4をコードするdna並びにt4フラグメントのaids治療への使用
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
DK0758383T3 (da) * 1994-05-06 2007-05-29 Roussy Inst Gustave Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof

Also Published As

Publication number Publication date
CA2293735A1 (fr) 1998-12-23
CN1181201C (zh) 2004-12-22
DE69825741T2 (de) 2005-09-01
CN1260833A (zh) 2000-07-19
ATE274057T1 (de) 2004-09-15
EP0977856A1 (fr) 2000-02-09
NO996097L (no) 2000-02-17
IL133544A (en) 2006-12-31
NO996097D0 (no) 1999-12-09
BR9810925A (pt) 2000-08-15
KR100552526B1 (ko) 2006-02-14
AU740147B2 (en) 2001-11-01
EP0977856B1 (fr) 2004-08-18
EP0900841A1 (fr) 1999-03-10
JP2002505582A (ja) 2002-02-19
ES2227862T3 (es) 2005-04-01
EA003086B1 (ru) 2002-12-26
EA200000038A1 (ru) 2000-06-26
DK0977856T3 (da) 2004-12-20
IL133544A0 (en) 2001-04-30
AU8435598A (en) 1999-01-04
WO1998058059A1 (fr) 1998-12-23
KR20010013539A (ko) 2001-02-26
DE69825741D1 (de) 2004-09-23
HK1027377A1 (en) 2001-01-12
EE9900581A (xx) 2000-08-15
PT977856E (pt) 2005-01-31

Similar Documents

Publication Publication Date Title
DK0977856T3 (da) LAG-3 splejsningsvarianter
AU7550098A (en) System for expressing hyperthermostable protein
DE60141546D1 (de) Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
CY1110982T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
AU1208597A (en) Cold-inducible promoter sequence
ATE534742T1 (de) Polypeptide und nukleinsäuren von phorphorymonas gingivalis
ATE189699T1 (de) Für spinnenseideprotein kodierende dns, dns enthaltender vektor, transformierte zelle und produkte davon
CY1106978T1 (el) Ενζυμα φωσφοδιεστερασης
NZ508439A (en) Novel endometriosis-associated gene
DK0870833T3 (da) Gener for ultrathermostabile proteaser
FI970892A7 (fi) Ilmentymiseltään kohdennetut retrovirusvektorit, jotka eivät ole itses tään inaktivoivia
ES2124694T3 (es) Clonacion de la n-metil-hidantoinasa.
HUP0001969A2 (hu) Az NNT-1 neurotróf faktor
DE59105231D1 (de) Klonierung und Überexpression von Glucose-6-Phosphat-Dehydrogenase aus Leuconostoc dextranicus.
SE9801098D0 (sv) Receptors
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
ATE304553T1 (de) Polypeptide mit wasserkanalaktivität und dna sequenzen
DE59109126D1 (de) N-Carbamoylsarcosin-Amidohydrolase, kloniert
ATE375390T1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
ATE301199T1 (de) Beta-primeverosidase gen
WO1999060117A3 (fr) Polypeptide prax-1

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090603